FRACTYL HEALTH, INC. 8-K

What Happened

• Fractyl Health, Inc. filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders held on June 10, 2026. Of 158,648,963 shares outstanding as of the April 17, 2026 record date, 112,236,206 shares (about 70.7% voting power) were represented.
• Three Class II directors were elected to three-year terms expiring at the 2029 annual meeting: Marc Elia, Clive Meanwell, M.B., Ch.B., M.D., and Ian Sheffield. The company also reported that Ernst & Young LLP was ratified as its independent registered public accounting firm for the 2026 fiscal year.

Key Details

• Shares outstanding (record date Apr 17, 2026): 158,648,963; shares represented at meeting: 112,236,206 (~70.7%).
• Director vote totals:
  • Marc Elia: For 65,196,683; Withheld 9,029,601; Broker non-vote 38,009,922.
  • Clive Meanwell: For 63,701,054; Withheld 10,525,230; Broker non-vote 38,009,922.
  • Ian Sheffield: For 73,761,318; Withheld 464,966; Broker non-vote 38,009,922.
• Ratification of auditors (Ernst & Young LLP): For 107,931,959; Against 189,715; Abstain 4,114,532.
• 8-K signed by Harith Rajagopalan, M.D., Ph.D., CEO, dated June 11, 2026.

Why It Matters

• Board continuity: Electing three Class II directors maintains the company’s governance team through the 2029 meeting, which can affect strategy and oversight.
• Auditor continuity: Ratifying Ernst & Young keeps the existing independent audit relationship in place for fiscal 2026, relevant to financial reporting and investor confidence.
• Voting participation and broker non-votes: Roughly 70.7% turnout shows substantial shareholder engagement; the sizable broker non-vote (~38 million shares) indicates many holders (typically institutional or retail via brokers) did not vote on director elections, which can affect close contests in future votes.